Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 4/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280831 | 0.79 | HDAC1 (0.38) | HDAC1HDAC6 | |
| SCHEMBL11996746 | 0.78 | RAB9A (0.36) | HDAC1HDAC6 | |
| SCHEMBL15263168 | 0.75 | FFAR1 (0.40) | XPO1FFAR1 | |
| SCHEMBL15428521 | 0.74 | P2RX7 (0.32) | — | |
| SCHEMBL21995669 | 0.73 | HDAC1 (0.40) | HDAC1HDAC6FFAR1 | |
| SCHEMBL15262270 | 0.72 | FFAR1 (0.51) | FFAR1 | |
| SCHEMBL11994464 | 0.71 | TP53 (0.39) | XPO1HDAC1HDAC6 | |
| SCHEMBL13748989 | 0.68 | HDAC1 (0.30) | HDAC1HDAC6 | |
| SCHEMBL17207244 | 0.68 | TYK2 (0.35) | HDAC1HDAC6 | |
| SCHEMBL12374151 | 0.67 | PSMB5 (0.34) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068768-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3068768-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3068768-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160257652-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2016-09-08 | — | — | US | disclosed |
| US-20160257652-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2016-09-08 | — | — | US | disclosed |
| US-20160257652-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2016-09-08 | — | — | US | disclosed |
| WO-2015073342-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073342-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257652-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | XPO1 4742/4885HDAC1 584/4885HDAC6 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.